Roxifiban
| Code | Size | Price |
|---|
| TAR-T24732-5mg | 5mg | £1,155.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T24732-50mg | 50mg | £1,982.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T24732-100mg | 100mg | £2,560.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Roxifiban is a prodrug. Following oral administration, whose methyl-ester is hydrolyzed to form the GPIIb/GPIIIA antagonist XV459.
CAS:
170902-47-3
Formula:
C21H29N5O6
Molecular Weight:
447.492
Purity:
0.98
SMILES:
CCCCOC(=O)N[C@@H](CNC(=O)C[C@H]1CC(=NO1)c1ccc(cc1)C(N)=N)C(=O)OC
References
1. Christen JR, Soubrier C, Martinez E, Roumieu V, Darmon O, Scandaliaris S, Picou L, Cuisset T, Grados A, Bernit E, Ebbo M, Harl? JR, Schleinitz N. [Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor]. Rev Med Interne. 2017 Nov;38(11):769-773. doi: 10.1016/j.revmed.2017.05.013. Epub 2017 Jul 6. French. PubMed PMID: 28690092.
2. Hantgan RR, Stahle MC. Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition. Biochemistry. 2009 Sep 8;48(35):8355-65. doi: 10.1021/bi900475k. PubMed PMID: 19640007.
3. Barrett YC, Ebling W, Pieniaszek H, Billheimer J, Seiffert D. Validation and implementation of drug-dependent antibody assays in clinical trials for safety monitoring of patients dosed with roxifiban, an orally bioavailable glycoprotein IIb/IIIa antagonist. J Pharm Biomed Anal. 2007 Aug 15;44(4):938-46. Epub 2007 Mar 31. PubMed PMID: 17485191.
4. Mousa SA. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography. Blood Coagul Fibrinolysis. 2007 Jan;18(1):55-60. PubMed PMID: 17179828.